drugset / Trial / NCT00005594
ISIS 2503 in Treating Patients With Advanced Cancer of the Pancreas
Phase 2
Completed
4 enrolled
University of Alabama at Birmingham
Ionis Pharmaceuticals · collabNational Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of ISIS 2503 in treating patients who have advanced cancer of the pancreas.
Timeline
- Start
- 2000-07
- Primary completion
- 2000-12
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ISIS 2503 | Antisense oligonucleotide | 6 mg/kg | Intravenous |